

Sabrina Paganoni

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7422537/publications.pdf>

Version: 2024-02-01

107
papers

3,819
citations

159525

30
h-index

149623

56
g-index

111
all docs

111
docs citations

111
times ranked

4779
citing authors

#	ARTICLE	IF	CITATIONS
1	Adaptive Platform Trials to Transform Amyotrophic Lateral Sclerosis Therapy Development. <i>Annals of Neurology</i> , 2022, 91, 165-175.	2.8	41
2	Using Smartphones to Reduce Research Burden in a Neurodegenerative Population and Assessing Participant Adherence: A Randomized Clinical Trial and Two Observational Studies. <i>JMIR MHealth and UHealth</i> , 2022, 10, e31877.	1.8	10
3	Statin Medications and Amyotrophic Lateral Sclerosis Incidence and Mortality. <i>American Journal of Epidemiology</i> , 2022, 191, 1248-1257.	1.6	7
4	ALSUntangled #64: butyrates. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2022, 23, 638-643.	1.1	6
5	Survival analyses from the <scp>CENTAUR</scp> trial in amyotrophic lateral sclerosis: Evaluating the impact of treatment crossover on outcomes. <i>Muscle and Nerve</i> , 2022, 66, 136-141.	1.0	30
6	Effect of sodium phenylbutyrate/taurursodiol on tracheostomy/ventilation-free survival and hospitalisation in amyotrophic lateral sclerosis: long-term results from the CENTAUR trial. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022, 93, 871-875.	0.9	37
7	An expanded access protocol of <scp>RT001</scp> in amyotrophic lateral sclerosisâ€”Initial experience with a lipid peroxidation inhibitor. <i>Muscle and Nerve</i> , 2022, 66, 421-425.	1.0	10
8	Long-term survival of participants in the <scp>CENTAUR</scp> trial of sodium phenylbutyrateâ€”taurursodiol in <scp>amyotrophic lateral sclerosis</scp>. <i>Muscle and Nerve</i> , 2021, 63, 31-39.	1.0	115
9	Effect of Ezogabine on Cortical and Spinal Motor Neuron Excitability in Amyotrophic Lateral Sclerosis. <i>JAMA Neurology</i> , 2021, 78, 186.	4.5	79
10	Smartphone data during the <scp>COVID</scp>-19 pandemic can quantify behavioral changes in people with <scp>ALS</scp>. <i>Muscle and Nerve</i> , 2021, 63, 258-262.	1.0	19
11	Pre-diagnostic plasma lipid levels and the risk of amyotrophic lateral sclerosis. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2021, 22, 133-143.	1.1	12
12	lbudilast (MN-166) in amyotrophic lateral sclerosis- an open label, safety and pharmacodynamic trial. <i>NeuroImage: Clinical</i> , 2021, 30, 102672.	1.4	21
13	Comparison of Two Clinical Upper Motor Neuron Burden Rating Scales in ALS Using Quantitative Brain Imaging. <i>ACS Chemical Neuroscience</i> , 2021, 12, 906-916.	1.7	9
14	Exploring the use of educational materials for increasing participation in a stretching program: a quality improvement project in people with motor neuron disease. <i>European Journal of Physical and Rehabilitation Medicine</i> , 2021, 57, 78-84.	1.1	1
15	Recruitment of Patients With Amyotrophic Lateral Sclerosis for Clinical Trials and Epidemiological Studies: Descriptive Study of the National ALS Registryâ€™s Research Notification Mechanism. <i>Journal of Medical Internet Research</i> , 2021, 23, e28021.	2.1	4
16	Research and Industry Partnerships in Physiatry. <i>American Journal of Physical Medicine and Rehabilitation</i> , 2021, 100, 990-995.	0.7	2
17	Patient reported outcomes in ALS: characteristics of the self-entry ALS Functional Rating Scale-revised and the Activities-specific Balance Confidence Scale. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2021, 22, 467-477.	1.1	10
18	Development and validation of a machine-learning ALS survival model lacking vital capacity (VC-Free) for use in clinical trials during the COVID-19 pandemic. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2021, 22, 22-32.	1.1	6

#	ARTICLE	IF	CITATIONS
19	The Impact of a Culinary Coaching Telemedicine Program on Home Cooking and Emotional Well-Being during the COVID-19 Pandemic. <i>Nutrients</i> , 2021, 13, 2311.	1.7	12
20	Prediagnostic Neurofilament Light Chain Levels in Amyotrophic Lateral Sclerosis. <i>Neurology</i> , 2021, 97, e1466-e1474.	1.5	20
21	Ultra-high field (7T) functional magnetic resonance imaging in amyotrophic lateral sclerosis: a pilot study. <i>NeuroImage: Clinical</i> , 2021, 30, 102648.	1.4	10
22	An integrated multi-omic analysis of iPSC-derived motor neurons from C9ORF72 ALS patients. <i>IScience</i> , 2021, 24, 103221.	1.9	27
23	Improved Function in a Runner With Hereditary Spastic Paraparesis With Use of Extracorporeal Shockwave Therapy. <i>American Journal of Physical Medicine and Rehabilitation</i> , 2021, 100, e66-e68.	0.7	1
24	Incidence of and Mortality From Amyotrophic Lateral Sclerosis in National Football League Athletes. <i>JAMA Network Open</i> , 2021, 4, e2138801.	2.8	35
25	Highest-Ranking Articles by Altmetric Attention Scores in Three Rehabilitation Journals. <i>PM and R</i> , 2020, 12, 324-326.	0.9	2
26	New directions in clinical trials for frontotemporal lobar degeneration: Methods and outcome measures. <i>Alzheimer's and Dementia</i> , 2020, 16, 131-143.	0.4	45
27	Primary lateral sclerosis (PLS) functional rating scale: PLS-specific clinimetric scale. <i>Muscle and Nerve</i> , 2020, 61, 163-172.	1.0	17
28	Evidence-Based Physiatry. <i>American Journal of Physical Medicine and Rehabilitation</i> , 2020, 99, 764-765.	0.7	8
29	Imaging Neurochemistry and Brain Structure Tracks Clinical Decline and Mechanisms of ALS in Patients. <i>Frontiers in Neurology</i> , 2020, 11, 590573.	1.1	16
30	The NEALS primary lateral sclerosis registry. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2020, 21, 74-81.	1.1	5
31	Trial of Sodium Phenylbutyrate-Taurursodiol for Amyotrophic Lateral Sclerosis. <i>New England Journal of Medicine</i> , 2020, 383, 919-930.	13.9	299
32	Optimizing telemedicine to facilitate amyotrophic lateral sclerosis clinical trials. <i>Muscle and Nerve</i> , 2020, 62, 321-326.	1.0	24
33	Patient reported outcome measures (PROMs) in amyotrophic lateral sclerosis. <i>Journal of Neurology</i> , 2020, 267, 1754-1759.	1.8	15
34	Amyotrophic lateral sclerosis care and research in the United States during the COVID-19 pandemic: Challenges and opportunities. <i>Muscle and Nerve</i> , 2020, 62, 182-186.	1.0	42
35	Preface: promoting research in PLS: current knowledge and future challenges. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2020, 21, 1-2.	1.1	6
36	Clinical care and therapeutic trials in PLS. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2020, 21, 67-73.	1.1	6

#	ARTICLE	IF	CITATIONS
37	Telemedicine to innovate amyotrophic lateral sclerosis multidisciplinary care: The time has come. <i>Muscle and Nerve</i> , 2019, 59, 3-5.	1.0	25
38	Soft Robotic Glove with Integrated Sensing for Intuitive Grasping Assistance Post Spinal Cord Injury. , 2019, , .		34
39	All-Cause and Cause-Specific Mortality Among Major League Baseball Players. <i>JAMA Internal Medicine</i> , 2019, 179, 1298.	2.6	3
40	Integration of a palliative care specialist in an amyotrophic lateral sclerosis clinic: Observations from one center. <i>Muscle and Nerve</i> , 2019, 60, 137-140.	1.0	30
41	Adjusted cost analysis of video televisits for the care of people with amyotrophic lateral sclerosis. <i>Muscle and Nerve</i> , 2019, 60, 147-154.	1.0	23
42	Design and results of a smartphone-based digital phenotyping study to quantify ALS progression. <i>Annals of Clinical and Translational Neurology</i> , 2019, 6, 873-881.	1.7	60
43	Mortality Among Professional American-Style Football Players and Professional American Baseball Players. <i>JAMA Network Open</i> , 2019, 2, e194223.	2.8	63
44	Nutritional counseling with or without mobile health technology: a randomized open-label standard-of-care-controlled trial in ALS. <i>BMC Neurology</i> , 2019, 19, 104.	0.8	13
45	Case 12-2019: A 60-Year-Old Man with Weakness and Difficulty Chewing. <i>New England Journal of Medicine</i> , 2019, 380, 1566-1574.	13.9	0
46	Prediagnostic plasma metabolomics and the risk of amyotrophic lateral sclerosis. <i>Neurology</i> , 2019, 92, 10.1212/WNL.0000000000007401.	1.5	26
47	Cromolyn sodium delays disease onset and is neuroprotective in the SOD1G93A Mouse Model of amyotrophic lateral sclerosis. <i>Scientific Reports</i> , 2019, 9, 17728.	1.6	26
48	Measuring the Impact of Research Using Conventional and Alternative Metrics. <i>American Journal of Physical Medicine and Rehabilitation</i> , 2019, 98, 331-338.	0.7	18
49	Cochrane Corners to Enhance Access to Evidence-Based Physiatry. <i>American Journal of Physical Medicine and Rehabilitation</i> , 2019, 98, 87-87.	0.7	1
50	Reply to Letter to the Editor Regarding Paganoni S. "Evidence-Based Physiatry: Managing Low Back Pain Wisely." <i>Am J Phys Med Rehabil</i> 2018;97:855. <i>American Journal of Physical Medicine and Rehabilitation</i> , 2019, 98, e111-e111.	0.7	0
51	Cooking Online With a Chef: Health Professionals'™ Evaluation of a Live Culinary Coaching Module. <i>Nutrition and Metabolic Insights</i> , 2019, 12, 117863881988739.	0.8	9
52	The "Nuts and Bolts" of Evidence-Based Physiatry. <i>American Journal of Physical Medicine and Rehabilitation</i> , 2019, 98, 942-943.	0.7	2
53	Evidence-Based Physiatry. <i>American Journal of Physical Medicine and Rehabilitation</i> , 2019, 98, 84-85.	0.7	0
54	A pilot trial of RNS60 in amyotrophic lateral sclerosis. <i>Muscle and Nerve</i> , 2019, 59, 303-308.	1.0	29

#	ARTICLE	IF	CITATIONS
55	Evidence-Based Physiatry. American Journal of Physical Medicine and Rehabilitation, 2018, 97, 531-532.	0.7	3
56	Experience with telemedicine in a multi-disciplinary ALS clinic. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2018, 19, 143-148.	1.1	39
57	Exploring the Use of Educational Material About Shoulder Dysfunction. American Journal of Physical Medicine and Rehabilitation, 2018, 97, 379-382.	0.7	4
58	Imaging of glia activation in people with primary lateral sclerosis. NeuroImage: Clinical, 2018, 17, 347-353.	1.4	29
59	Implementation of a Multifaceted Interactive Electrodiagnostic Medicine Workshop in a Physical Medicine and Rehabilitation Residency Program. American Journal of Physical Medicine and Rehabilitation, 2018, 97, 134-140.	0.7	2
60	Urate levels predict survival in amyotrophic lateral sclerosis: Analysis of the expanded Pooled Resource Open-Access ALS clinical trials database. Muscle and Nerve, 2018, 57, 430-434.	1.0	39
61	Evidence-Based Physiatry. American Journal of Physical Medicine and Rehabilitation, 2018, 97, 855-855.	0.7	2
62	Evidence-Based Physiatry. American Journal of Physical Medicine and Rehabilitation, 2018, 97, 920-920.	0.7	2
63	Evidence-Based Physiatry. American Journal of Physical Medicine and Rehabilitation, 2018, 97, 763-763.	0.7	2
64	Prediagnostic plasma branched chain amino acids and the risk of amyotrophic lateral sclerosis. Neurology, 2018, 92, 10.1212/WNL.0000000000006669.	1.5	5
65	Pilot trial of inosine to elevate urate levels in amyotrophic lateral sclerosis. Annals of Clinical and Translational Neurology, 2018, 5, 1522-1533.	1.7	31
66	Urate mitigates oxidative stress and motor neuron toxicity of astrocytes derived from ALS-linked SOD1 mutant mice. Molecular and Cellular Neurosciences, 2018, 92, 12-16.	1.0	18
67	Assisting hand function after spinal cord injury with a fabric-based soft robotic glove. Journal of NeuroEngineering and Rehabilitation, 2018, 15, 59.	2.4	155
68	Integrated magnetic resonance imaging and [¹¹ C]PBR28 positron emission tomographic imaging in amyotrophic lateral sclerosis. Annals of Neurology, 2018, 83, 1186-1197.	2.8	75
69	Evidence-Based Physiatry. American Journal of Physical Medicine and Rehabilitation, 2018, 97, 602-603.	0.7	1
70	Integrated imaging of [11C]-PBR28 PET, MR diffusion and magnetic resonance spectroscopy 1H-MRS in amyotrophic lateral sclerosis. NeuroImage: Clinical, 2018, 20, 357-364.	1.4	45
71	Evidence-Based Physiatry. American Journal of Physical Medicine and Rehabilitation, 2018, 97, 679-679.	0.7	2
72	Telehealth in Physical Medicine and Rehabilitation: A Narrative Review. PM and R, 2017, 9, S51-S58.	0.9	137

#	ARTICLE	IF	CITATIONS
73	Developing multidisciplinary clinics for neuromuscular care and research. <i>Muscle and Nerve</i> , 2017, 56, 848-858.	1.0	38
74	Outcome measures in the idiopathic inflammatory myopathies. <i>Neurology</i> , 2017, 89, 20-21.	1.5	2
75	Urate as a Marker of Risk and Progression of Neurodegenerative Disease. <i>Neurotherapeutics</i> , 2017, 14, 148-153.	2.1	75
76	Vitamin D levels are associated with gross motor function in amyotrophic lateral sclerosis. <i>Muscle and Nerve</i> , 2017, 56, 726-731.	1.0	22
77	Functional Ambulation in a Patient With Primary Lateral Sclerosis Using a Lower Extremity Robotic Exoskeleton. <i>Archives of Physical Medicine and Rehabilitation</i> , 2017, 98, e69.	0.5	0
78	Estimating Bradykinesia in Parkinson's Disease with a Minimum Number of Wearable Sensors. , 2017, , .		12
79	Causal inference methods to study gastric tube use in amyotrophic lateral sclerosis. <i>Neurology</i> , 2017, 89, 1483-1489.	1.5	18
80	Phase IIa trial of fingolimod for amyotrophic lateral sclerosis demonstrates acceptable acute safety and tolerability. <i>Muscle and Nerve</i> , 2017, 56, 1077-1084.	1.0	37
81	Serum urate at trial entry and ALS progression in EMPOWER. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2017, 18, 120-125.	1.1	20
82	Ultra high-field (7tesla) magnetic resonance spectroscopy in Amyotrophic Lateral Sclerosis. <i>PLoS ONE</i> , 2017, 12, e0177680.	1.1	45
83	Functional Decline is Associated with Hopelessness in Amyotrophic Lateral Sclerosis (ALS). <i>Journal of Neurology & Neurophysiology</i> , 2017, 08, .	0.1	17
84	Palliative Care Issues in Amyotrophic Lateral Sclerosis. <i>American Journal of Hospice and Palliative Medicine</i> , 2016, 33, 84-92.	0.8	41
85	Comprehensive rehabilitative care across the spectrum of amyotrophic lateral sclerosis. <i>NeuroRehabilitation</i> , 2015, 37, 53-68.	0.5	53
86	Reply. <i>Muscle and Nerve</i> , 2015, 52, 691-691.	1.0	2
87	Pre-morbid type 2 diabetes mellitus is not a prognostic factor in amyotrophic lateral sclerosis. <i>Muscle and Nerve</i> , 2015, 52, 339-343.	1.0	25
88	Complementary and Alternative Therapies in Amyotrophic Lateral Sclerosis. <i>Neurologic Clinics</i> , 2015, 33, 909-936.	0.8	37
89	Trials of Antidiabetic Drugs in Amyotrophic Lateral Sclerosis: Proceed with Caution?. <i>Neurodegenerative Diseases</i> , 2014, 13, 205-208.	0.8	20
90	Clinical Reasoning: A 20-year-old woman with rapidly progressive weakness. <i>Neurology</i> , 2014, 82, e200-4.	1.5	0

#	ARTICLE	IF	CITATIONS
91	Diagnostic timelines and delays in diagnosing amyotrophic lateral sclerosis (ALS). <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2014, 15, 453-456.	1.1	157
92	Disease Burden in Upper Motor Neuron Syndromes. <i>Journal of Clinical Neuromuscular Disease</i> , 2014, 16, 104-105.	0.3	5
93	Outcome measures in amyotrophic lateral sclerosis clinical trials. <i>Clinical Investigation</i> , 2014, 4, 605-618.	0.0	50
94	Clinical Improvement of Monomelic Amyotrophy After Avoidance of Sustained Neck Flexion. <i>Journal of Clinical Neuromuscular Disease</i> , 2014, 15, 191-192.	0.3	3
95	Rehabilitation in amyotrophic lateral sclerosis: Why it matters. <i>Muscle and Nerve</i> , 2014, 50, 4-13.	1.0	73
96	Electrodiagnostic Evaluation of Myopathies. <i>Physical Medicine and Rehabilitation Clinics of North America</i> , 2013, 24, 193-207.	0.7	92
97	High-Fat and Ketogenic Diets in Amyotrophic Lateral Sclerosis. <i>Journal of Child Neurology</i> , 2013, 28, 989-992.	0.7	18
98	Uric acid levels predict survival in men with amyotrophic lateral sclerosis. <i>Journal of Neurology</i> , 2012, 259, 1923-1928.	1.8	99
99	Muscle synergy patterns as physiological markers of motor cortical damage. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 14652-14656.	3.3	479
100	What does body mass index measure in amyotrophic lateral sclerosis and why should we care?. <i>Muscle and Nerve</i> , 2012, 45, 612-612.	1.0	6
101	Osteoid Osteoma of the Spinoglenoid Notch Mimicking Cervical Radiculopathy. <i>PM and R</i> , 2011, 3, 280-283.	0.9	0
102	Body mass index, not dyslipidemia, is an independent predictor of survival in amyotrophic lateral sclerosis. <i>Muscle and Nerve</i> , 2011, 44, 20-24.	1.0	265
103	Association of spinocerebellar ataxia type 3 and spinocerebellar ataxia type 8 microsatellite expansions: Genetic counseling implications. <i>Movement Disorders</i> , 2008, 23, 154-155.	2.2	11
104	Neurite extension in central neurons: a novel role for the receptor tyrosine kinases Ror1 and Ror2. <i>Journal of Cell Science</i> , 2005, 118, 433-446.	1.2	71
105	Differential subcellular localization of Ror tyrosine kinase receptors in cultured astrocytes. <i>Glia</i> , 2004, 46, 456-466.	2.5	12
106	Expression and subcellular localization of Ror tyrosine kinase receptors are developmentally regulated in cultured hippocampal neurons. <i>Journal of Neuroscience Research</i> , 2003, 73, 429-440.	1.3	37
107	The Formation of Synapses in the Central Nervous System. <i>Molecular Neurobiology</i> , 2002, 26, 069-080.	1.9	15